标题：阿帕替尼单药及合用替吉奥治疗晚期胃癌疗效观察

      作者：纪华清 1，桂宏亮 1，束宽山 2，李兴保 1，王辉 1    铜陵市人民医院肿瘤内科 1、胃肠外科 2，安徽 铜陵 244000

      卷次： 2019年30卷5期

      【摘要】 目的 探讨阿帕替尼单药及合用替吉奥治疗晚期胃癌的临床疗效。方法 选取2015年7月至2017年12月铜陵市人民医院收治的40例晚期胃癌患者作为研究对象，采用随机数表法分为观察组和对照组各20例，对照组患者给予阿帕替尼单药治疗，观察组患者在对照组基础上合用替吉奥治疗，每3周为一个疗程。连续用药2个疗程后比较两组患者的临床治疗效果及毒副反应情况，采用卡氏行为状态(KPS)评分评价两组患者治疗后的生活质量水平。结果 观察组患者治疗后的疾病控制率为 90.0%，明显高于对照组的 60.0%，差异有统计学意义(P<0.05)，但其总缓解率仅为25.0%，略高于对照组的10.0%，差异无统计学意义(P>0.05)；观察组和对照组患者治疗后手足综合征、白细胞减少发生率(30.0% vs 25.0%、75.00% vs 70.0%)比较，观察组较对照组略有提高，但差异均无统计学意义(P>0.05)；观察组患者的生活质量改善及稳定者分别为 25.0%和 55.0%，高于对照组的 15.0%和 30.0%，但差异均无统计学意义(P>0.05)，总有效率为 80.0%，明显高于对照组的 45.5%，差异具有统计学意义(P<0.05)。结论 与阿帕替尼单一用药比较，联合替吉奥治疗晚期胃癌短期疗效较为突出，其能在一定程度上改善患者的生活质量，用药期间药物毒副反应虽有所增加，但在患者可耐受范围内。
      【关键词】 阿帕替尼；替吉奥；联合用药；晚期胃癌；不良反应；生活质量
      【中图分类号】 R735.2 【文献标识码】 A 【文章编号】 1003—6350（2019）05—619—03T

herapeutic effect of Apatinib monotherapy combined with Tegafur & Gimeracil & Oteracil Capsule drug in thetreatment of advanced gastric cancer.
JI Hua-qing 1, GUI Hong-liang 1, SHU Kuan-shan 2, LI Xing-bao 1, WANG Hui 1.Department of Internal Medicine-Oncology 1, Department of Gastrointestinal Surgery 2, Tongling People's Hospital, Tongling244000, Anhui, CHINA
【Abstract】 Objective To explore the clinical efficacy of Apatinib monotherapy in combination with Tegafur &Gimeracil & Oteracil (TGO) Capsule in the treatment of advanced gastric cancer. Methods A total of 40 patients withadvanced gastric cancer admitted to Tongling People's Hospital from July 2015 to December 2017 were selected as sub-jects. They were randomly divided into observation group and control group, with 20 cases in each group. Patients in thecontrol group were treated with Apatinib monotherapy, and patients in the observation group were given TGO capsule onthe basis of the control group, with every 3 weeks for a course of treatment. The clinical efficacy and side effects of thetwo groups were compared after two courses of continuous medication, and the the quality of life after treatment wasevaluated by the Karnofsky Performance Status (KPS) scale. Results After treatment, the disease control rate of the ob-servation group was 90.0%, which was significantly higher than 60.0% of the control group (P<0.05); but the total remis-sion rate was only 25.0%, which was slightly higher than 10.0% of the control group (P>0.05). The comparison betweenthe incidence of hand-foot syndrome and leukopenia after treatment in the observation group and the control group(30.0% vs 25.00%, 75.00% vs 70.0%, respectively) showed that the observation group slightly improved compared withthe control group (P>0.05). The quality of life improvement and stability in the observation group were respectively25.0% and 55.0%, which were higher than corresponding 15.0% and 30.0% in the control group (P>0.05). The total ef-fective rate was 80.0% in the observation group, which was significantly higher than 45.5% in the control group (P<0.05). Conclusion Compared with Apatinib monotherapy, the short-term efficacy of the combination of TGO therapyis more prominent in the treatment of advanced gastric cancer, which can improve the quality of life of patients to some extent. Al-though the side effects of drug have increased during the course of treatment, it is within the tolerable range of patients.
      【Key words】 Apatinib; TGO capsule; Combinated therapy; Advanced gastric cancer; Side effects; Quality of life·短篇论著·doi:10.3969/j.issn.1003-6350.2019.05.024